In recent years， the researches on chimeric antigen receptor（CAR） engineered T lymphocytes in curing cancer have made great progresses. CAR has several technical advantages， such as endowing great targeting ability to CAR-engineered T cells， breaking the state of immune tolerance and so on， which make great progress in curing Hematology. Because of existed off-target effects of solid tumor and the poor penetration of immune cells into the tumor tissue， this application is still in phase I clinical trial. This paper will make a review of the application of CAR enjineered T lymphocyte to some solid tumor experiments.

Objective  To analyze the methylation status of promoter of O6-methylguanine-DNA methyltransferase （MGMT） gene and its relationship with clinicopathological features and prognosis of glioma. Methods The methylation level of MGMT was detected by methylation specific polymerase chain reaction （MSP） in 70 glioma tissues and 14 normal brain tissues of non-tumor patients who underwent surgical treatment from January 2012 to June 2013. The relationship between MGMT methylation and clinicopathological features was analyzed. Overalll survival （OS） of patients with high and low grade glioma with different MGMT methylation status was compared. Cox proportional regression model was used to analyze the factors affecting OS in low-grade glioma patients. Results Of 70 glioma patients， 48 （68.6％） had MGMT promoter methylation， while only 2 （14.3％） had MGMT methylation in normal brain tissues （P＜0.05）. MGMT methylation was not correlated with age， sex， tumor type， KPS score， p53 and Ki-67 expression （P＞0.05）， but with pathological grade （P＜0.05）. The median OS of MGMT methylated glioma patients was 30 months， significantly longer than that of non-methylated glioma patients for 11 months （P＜0.05）. Univariate analysis showed that WHO pathological grade， alkylating agent chemotherapy and MGMT methylation were associated with OS in low-grade glioma patients （P＜0.05）. Multivariate analysis showed that WHO grade Ⅱ， non-alkylation chemotherapy and MGMT non-methylation were independent risk factors for OS in low-grade glioma patients （P＜0.05）. Conclusion MGMT methylation is related to the occurrence and development of glioma. It has certain value in judging the malignancy of glioma， evaluating prognosis and guiding clinical treatment.

The high mobility group protein A（HMGA） family is composed of four proteins. HMGA2 is one of the family. HMGA2 involves in epithelialmesenchymal transition， and plays a crucial role in maintaining the differentiation potential and the selfrenewal of neural stem cells（NSCs）.HMGA2 is able to process a number of different mechanisms involved in the regulation of biological events. Overexpression of HMGA2 has been observed in a variety of malignant tumors and often correlates with poor prognosis. In this review, we summarize the latest progresses on HMGA2 in cancer.

The soaring cost of new antitumor drugs has prompted calls for more attention to the value of these products. In response to rapidly increasing health care spending， several organizations such as ASCO, ESMO, ICER, NCCN and DrugAbacus have developed frameworks to systematically assess the value of new drugs. Value assessment frameworks vary in their definition of components of value and their approach to assessment. This review analyzes and discusses several assessment frameworks in foreign countries by reviewing and synthesizing relevant literature， in order to help us build a framework for the evaluation of the value of antitumor drugs applicable to our country and carry out value-based treatment decisions.

Tumor-draining lymph node，abbreviated as TDLN， refers to the lymph node affected by tumor cells through lymphatic ducts， including various types of immune cells， like nature killer cells， T cells， antigen presenting cells and B cells. Because of the presence of these immune cells and the unique location of TDLN located downstream of the tumor， TDLN becomes an important site of anti-tumor immune response. However， TDLN， often developing immune tolerance to the tumor， becomes the transfer relay station of tumor cells to other tissues. In the immunotherapy of TDLN， except vitro-activate cell therapy and in vivo-activated cell therapy， some new treatments， such as targeted therapy， are becoming the focus of research. This article reviews the immunological properties of TDLN， and the mechanism and research progress of TDLN related immunotherapy.

The coagulation mechanism is abnormal in malignant tumor patients， such as the increased platelet count and increased platelet aggregation. Therefore， the cancer associated thrombosis is one of the most common complication in malignant tumor patients. According to the epidemic investigation of maglignant tumor and thrombus， the risk of venous thromboembolism（VTE） is about 4-7 times higher in cancer patients than that of nontumor patients. Risk factors for cancer associated thrombosis include tumor types， patients characteristics and treatment related factors. We can prevent and treat tumor associated thrombosis according to its biological markers and risk models. The heparin or low molecular weight heparin is often applied in the treatment of cancer patients with VTE. But the thrombocytopenia often occurs after the treatment of heparin therapy， which causes the skin and organ extensive bleeding in cancer patients. Therefore， this paper will briefly review the pathogenesis of maglignat tumor associated thrombosis， the clinical and laboratory diagnosis of thrombocytopenia after the heparin treatment and the progress of clinical treatment， which can be useful for discussion and reference for the clinicians.

ObjectiveTo investigate the efficacy and safety of chidamide combined with paclitaxel liposome in the treatment of advanced breast cancer with negative HER2 expression. 
MethodsA total of 41 patients with advanced HER2 negative breast cancer from May 2017 to November 2017， who failed in 2 regimens of chemotherapy were enrolled and randomly divided into observation group （n=20） and control group （n=21）. Patients in observation group were given chidamide tablets （30 mg oral administration， twice per week for 2 months） and paclitaxel liposome （175 mg／m2 iv， 21 days was a cycle for 3 cycles）. In addition to paclitaxel liposome, patients in control group were given placebo （30 mg oral administration， twice per week for 2 months）. Response rate， disease control rate and progressionfree survival were analyzed. 
ResultsAll patients were evaluable for the efficacy. In observation group， there were 5 cases of CR， 7 cases of PR， 5 cases of SD and 3 cases of PD. RR was 600％ and DCR was 850％. In control group， there were 3 cases of CR， 3 cases of PR， 5 cases of SD and 10 cases of PD. RR was 286％ and DCR was 524％. The RR and DCR in observation group were higher than those in control group （P＜005）. The median PFS was 52 months in observation group， higher than 31 months in control group （P＜005）. The main adverse reactions were gastrointestinal reactions and bone marrow suppression， mainly in grade 12. The incidences of leukopenia， thrombocytopenia and nausea／vomiting were higher in observation group than in control group （P＜005）. 
ConclusionChidamide combined with paclitaxel liposome for advanced breast cancer with negative HER2 expression has good efficacy and the adverse effects are tolerable.

 Chemotherapy is an important therapeutic strategy for cancer treatment， however， chemoresistance is a major challenge. Recently， emerging evidences suggest that abnormal changes in the Notch signaling pathway are involved in the development and chemotherapy resistance of human malignancies. Notch signaling pathway is widely expressed in a variety of tumor cells， and it promotes tumor stem cell （CSC） phenotype， epithelial-mesenchymal transition （EMT）， and interaction with other signaling pathways， resulting in tumor resistance to chemotherapeutic drug. Therefore， this article will provide a brief overview of what is currently known about Notch signaling and its related regulatory mechanism. Moreover， down-regulation of Notch pathway could enhance drug sensitivity， which may provide a novel approach for the treatment of cancer.

 The International Agency for Research on Cancer (IARC) estimates 36 cancer incidence rate and mortality rates in 185 countries/regions through GLOBOCAN 2020 database. Globocan2020 database shows that cervical cancer is the fourth largest tumor in women in the world, whether it is morbidity or mortality. The harm of cervical cancer to women's health and its prevention and treatment are important public health issues facing the world. This paper will summarize and compare the incidence and death prevalence of cervical cancer in the world and China from the aspects of population characteristics, regional distribution and time change trend, and combined with the reported human papillomavirus and other risk factors, primary prevention and secondary prevention strategies of cervical cancer, in order to provide scientific clues for the prevention and treatment strategies of cervical cancer in the future.

Radiation therapy occupies an irreplaceable position for cancer therapy. Most tumors are radiation resistant with hypoxic cells，so it's important to increase the radiosensitization. At present，the radiosensitization concept has developed including DNA damage，angiogenesis，cell signal transduction，cell cycle dysfunction, apoptosis，and other fields. This article reviews the recent literature and the relevant issues concerning the role of the mechanism，strategy，and drugs of radiosensitization.

Natural killer T （NKT） cell is a kind of important independent lymphocyte subsets. Studies have shown that it plays an important role in the process of the bodys immune response. Different NKT cells and their functions have been found and the influence of different subsets of tumor immune is not the same. The interaction mechanism between subsets is not very clear and needs further exploration. An indepth understanding of NKT cells in the tumor immune function has important significance for the treatment of tumors.

Objective To investigate the effect of lobaplatin （LBP） on proliferation and apoptosis of human hepatic cancer cell line HepG2 and possible mechanisms. Methods Logarithmic growth phase HepG2 cells were used for study. Different concentrations of LBP （0， 2.5， 5， 10， 20 μmol／L） treated HepG2 cells for 48 hours. General morphological changes were observed under an optical microscope. MTS assay was used to detect the relative viability of HepG2 cells， and IC50 （50％ inbibiting concentration） was calculated. Hoechst 33258 staining and flow cytometry based on Annexin V-PI double staining were used to measure the apoptosis of HepG2 cells. Western blotting assay was used to detect the expression changes of Bax， Bak， Bcl-2， Bcl-XL，Mcl-1， Survivin and PARP-1 protein. Results Cell morphological observation showed LBP treated HepG2 cells for 48 hours with the increase of drug concentration the HepG2 cell density decreased， the number of swelling cytoplasm and floating rounded cells increased significantly. Hoechst33258 staining to test the typical apoptotic cells with nuclear fragmentation or nuclear condensation showed that LBP induced apoptosis， in a dose-dependent manner. MTS assay indicated LBP greatly inhibited HepG2 cell growth in a dose- and time-dependent manner. The proliferation rates of HepG2 cells treated with 2.5, 5, 10, 20 μmol/L LBP for 48 h were （92.11±1.79）％， （65.87±1.78）％，（51.57±0.81）％ and （33.11±1.47）％. After LBP treatment HepG2 cell for 48 hours the value of IC50 was 13.28 μmol／L. The apoptotic rates of HepG2 cells treated with 2.5, 5, 10, 20 μmol/L LBP for 48 h were （11.64±0.85）%, （20.99±2.21）%, （33.02±2.30）% and （40.77±1.58）%. The difference was significant between LBP treat group and control group （P＜0.05）. Western blotting analysis showed that 2.5, 5, 10, 20 μmol/L LBP down-regulated Bcl-2 and Mcl-1 protein expression， whereas upregulated Bax， Bid and PARP-1 expression. Bcl-XL， Bak and Survivin protein expression was not changed. Conclusion LBP significantly exerts anti-cancer effects through inducing cell growth inhibition and apoptosis， the possible mechanism is related to the regulation of apoptosis related proteins including Bax， Bid， Bcl-2 and Mcl-1.